000 01349nam a2200169Ia 4500
003 OSt
005 20260718102240.0
008 230508s2022 xx 000 0 und d
050 _aAllied HD 9666.4
_bL36 2022
100 1 _aLaMattina, John L.
245 1 0 _aPharma and profits :
_bbalancing innovation, medicine, and drug prices /
_cJohn L. LaMattina.
264 _aHoboken, NJ :
_bJohn Wiley & Sons,
_c2022.
300 _axii, 100 pages ;
_c23 cm.
500 _aIncludes index.
505 0 _ach. 1. The $1000 pill: the fiscal consequences of curing hepatitis C — ch. 2. Enter the players: FDA approval does not guarantee commercial success — ch. 3. Pandemic: mRNA vaccine and the race for a cure — ch. 4. Federal investment in r&d: why the government does not deserve a piece of biopharma’s profits? — ch. 5. Inaulin: the true cost of a 100-year-old drug — ch. 6. The costly alzheimer’s disease drug: a questionable breakthrough — ch. 7. Gene therapy: how much a life worth? — ch. 8. Proving the value of expensive drug: should we pay for drugs whose ultimate value is unknown? — cn. 9. Generic drugs: built-in cost controls — ch. 10. About those soaring pharma profits: are they driving healthcare costs? — ch. 11. Schemes to lower drug prices: the impact of reduced resources on r&d.
942 _2lcc
_cBK
_kEAC Cavite-Allied
999 _c33453
_d33453